By admin 
In a move that has reignited hope for thousands of families across the United Kingdom, the National Institute for Health and Care Excellence (NICE) announced on Friday that it has officially reopened its review into two landmark Alzheimer’s treatments, Kisunla and Leqembi. This reversal comes after the agency’s initial determination that the drugs, while scientifically innovative, did not meet the stringent cost-effectiveness thresholds required for routine use within the taxpayer-funded National Health Service (NHS). The decision to revisit these therapies follows a series of high-stakes appeals by the drugmakers—Eli Lilly for Kisunla (donanemab) and the partnership of Eisai and Biogen for Leqembi (lecanemab)—who argued that the previous evaluations undervalued the profound societal benefits of delaying the progression of a devastating neurodegenerative disease.
The backdrop of this administrative pivot is a long-standing tension between the rapid pace of medical innovation and the finite budgets of socialized healthcare systems. In 2024, both Kisunla and Leqembi achieved a major milestone by securing regulatory authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). This approval confirmed that the drugs met safety and efficacy standards for use in the U.K. However, in the British healthcare landscape, regulatory approval is only the first hurdle. For a medicine to be accessible to the general public through the NHS, it must receive a positive recommendation from NICE, the body tasked with ensuring that the government receives "value for money" for every pound spent on healthcare.
The initial rejections by NICE were rooted in a complex calculation of "Quality-Adjusted Life Years" (QALYs), a metric used to compare the health benefits of different treatments. For both therapies, NICE’s independent committees initially concluded that the clinical benefits—while statistically significant in slowing cognitive decline—were too modest to justify the high price tags of the drugs themselves and the massive secondary costs associated with their administration. Beyond the sticker price of the medication, the NHS would be required to overhaul its diagnostic and monitoring infrastructure. These drugs target amyloid-beta plaques in the brain, necessitating specialized PET scans or cerebrospinal fluid tests for diagnosis, bi-weekly or monthly intravenous infusions, and frequent MRI scans to monitor for potentially dangerous side effects such as Amyloid-Related Imaging Abnormalities (ARIA), which include brain swelling and micro-hemorrhages.
The drugmakers’ successful appeal signifies a potential shift in how the value of Alzheimer’s treatments is calculated. Eli Lilly and Eisai/Biogen have consistently argued that the standard NICE model fails to account for the "spillover" benefits of slowing dementia. These include the reduced burden on unpaid family caregivers, the delay in patients needing expensive long-term residential care, and the broader economic impact of keeping individuals in the workforce or living independently for longer. By reopening the review, NICE has signaled a willingness to scrutinize the economic modeling once more, potentially opening the door for a "managed access agreement" where the drugs could be provided to a subset of patients while further real-world data is collected.
To understand the weight of this decision, one must look at the clinical data that defines these two therapies. Leqembi, the first of the two to receive global attention, demonstrated in its Phase 3 "Clarity AD" clinical trial that it could slow cognitive and functional decline by 27% over 18 months in patients with early-stage Alzheimer’s. While 27% may sound incremental, for a patient, it can represent several additional months or even years of being able to recognize family members, perform daily tasks, or live at home. Kisunla, Eli Lilly’s entry into the market, showed even more robust results in its "TRAILBLAZER-ALZ 2" trial, slowing decline by up to 35% in a specific group of patients with low-to-medium levels of tau, another protein associated with Alzheimer’s progression.
However, the medical community remains divided on the "clinical meaningfulness" of these percentages. Critics of the drugs point out that while the results are statistically significant, they may not be easily discernible to an individual patient or their family in the short term. Furthermore, the risks are non-trivial. In clinical trials, a significant minority of patients experienced ARIA. While most cases were asymptomatic and resolved on their own, a small number of instances were severe or even fatal. NICE’s original assessment weighed these risks and the intensive monitoring required against the measured cognitive benefits and found the balance wanting.
The reopening of the review also highlights the immense pressure exerted by patient advocacy groups. Organizations such as Alzheimer’s Research UK and the Alzheimer’s Society have been vocal in their disappointment over the initial "no" from NICE. They argue that after decades of failed clinical trials and a total lack of disease-modifying treatments, it is unethical to deny British patients access to the first generation of drugs that actually tackle the underlying biology of the disease. They point to the United States, where the Food and Drug Administration (FDA) has granted broad approval, and where Medicare has established a pathway for coverage, albeit with data-collection requirements.
The challenge for the NHS is not just the cost of the drug, but the "readiness" of the system. Currently, the U.K. suffers from a significant shortage of the diagnostic tools required to identify eligible patients. Most dementia diagnoses in the U.K. are still made based on clinical symptoms rather than biomarker testing. To implement Kisunla or Leqembi, the NHS would need to dramatically increase its capacity for PET imaging and lumbar punctures. There is also the logistical hurdle of the infusion centers themselves. Unlike a pill that can be taken at home, these monoclonal antibodies require hospital-based administration. In an NHS already struggling with elective surgery backlogs and staffing shortages, the introduction of a high-demand service for a disease as prevalent as Alzheimer’s is a daunting prospect.
Economic analysts suggest that for NICE to reach a "yes," the pharmaceutical companies may need to offer significant confidential discounts or agree to a performance-based pricing model. In such a model, the NHS would only pay the full price if the drug meets certain benchmarks of efficacy in the real-world population. This approach has been used previously for high-cost cancer drugs and gene therapies. The fact that NICE has agreed to look again suggests that there may be new flexibility in the negotiations or that the manufacturers have provided new evidence regarding the long-term trajectory of patients who stop treatment once their amyloid plaques have been cleared—a unique feature of Eli Lilly’s Kisunla.
The global context of this decision cannot be overstated. The European Medicines Agency (EMA) initially took a hardline stance, recommending against the approval of Leqembi in mid-2024, citing concerns over the risk of ARIA. However, upon re-examination, the EMA shifted its position to recommend approval for a restricted group of patients who do not carry two copies of the ApoE4 gene, which is linked to a higher risk of side effects. This European shift likely put additional pressure on U.K. officials to ensure that British patients are not left behind their continental counterparts.
As the review progresses, the focus will turn to the specific "sub-populations" that might benefit most. It is possible that NICE will recommend the drugs only for patients with the highest risk of rapid progression or those with the lowest risk of side effects. This "targeted" approach could help manage the budget impact while still establishing a foothold for disease-modifying therapy in the U.K.
For the millions of people in the U.K. affected by Alzheimer’s—either as patients or as the "invisible army" of caregivers—the news that NICE is reopening the door is a flicker of light in a long-dark room. It represents a recognition that the status quo of "watchful waiting" and symptomatic management is no longer acceptable in an era where the molecular roots of dementia are finally being untangled. The coming months of deliberation will be a litmus test for the U.K.’s ability to integrate high-cost, high-innovation medicine into a universal healthcare system. The world will be watching closely, as the outcome will likely set a precedent for how other nations with similar healthcare models approach the impending wave of new Alzheimer’s therapies.
In the interim, the pharmaceutical giants involved have expressed a cautious optimism. A spokesperson for Eli Lilly noted that the company is "committed to working collaboratively with NICE" to find a path forward that recognizes the full value of Kisunla. Similarly, Eisai and Biogen have emphasized their dedication to ensuring that Leqembi is not just a scientific breakthrough on paper, but a tangible option for patients in the U.K. As the technical committees re-convene, the debate will continue to oscillate between the cold mathematics of health economics and the warm, urgent reality of human suffering, with the hope that a middle ground can finally be reached.